PDCD1 and chronic obstructive pulmonary disease: All included patients received neoadjuvant immune checkpoint inhibitors (PD-1 inhibitors and PD-L1 inhibitors) combined with chemotherapy: 25 and 5 patients, respectively, in the COPD group, and 38 and 6 patients, respectively, in the non-COPD group.